Dr. Reddy’s Lab, UCB enter into agreement for Briviact

09 Jul 2018 Evaluate

Dr. Reddy’s Laboratories and UCB, a biopharmaceutical company, have entered into a distribution and co-promotion agreement for Briviact, a brand of brivaracetam. The agreement grants Dr. Reddy’s the exclusive right to distribute Briviact in India.

Briviact (brivaracetam) is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1175.55 -10.90 (-0.92%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×